Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101

British Journal of Dermatology

Volumn 158, Issue 3, 2008, Pages 578-586

  Frei, G M ^a   Kremer, M ^b   Hanschmann, K M ^b   Krause, S ^b   Albeck, M ^a   Sredni, B ^a   Schnierle, B S ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Apoptosis; AS101; Cutaneous T cell lymphoma; Reactive oxygen species

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; CASPASE 3; CASPASE 9; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DOSE RESPONSE; GROWTH INHIBITION; IMMUNOMODULATION; IN VITRO STUDY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; MYCOSIS FUNGOIDES; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ETHYLENES; MICE; MICE, NUDE; MODELS, ANIMAL; MYCOSIS FUNGOIDES; SKIN NEOPLASMS;

EID: 39049085272     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08414.x     Document Type: Article

References (43)

1. Chiarion-Sileni V, Bononi A, Fornasa CV et al. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 2002 95 : 569 75.
2. Kaltoft K, Hansen BH, Thestrup-Pedersen K. Cytogenetic findings in cell lines from cutaneous T-cell lymphoma. Dermatol Clin 1994 12 : 295 304.
3. Thaler S, Burger AM, Schulz T et al. Establishment of a mouse xenograft model for mycosis fungoides. Exp Dermatol 2004 13 : 406 12.
4. Thaler S, Burger AM, Schulz T et al. MLV/HIV-pseudotyped vectors: a new treatment option for cutaneous T cell lymphomas. Mol Ther 2003 8 : 756 61.
5. Sredni B, Caspi RR, Klein A et al. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 1987 330 : 173 6.
6. Sredni B, Tichler T, Shani A et al. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101. J Natl Cancer Inst 1996 88 : 1276 84.
7. Kalechman Y, Strassmann G, Albeck M et al. Up-regulation by ammonium trichloro (dioxoethylene-O,O') tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101. J Immunol 1998 161 : 3536 42.
8. Hayun M, Naor Y, Weil M et al. The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway. Biochem Pharmacol 2006 72 : 1423 31.
9. Sredni B, Xu RH, Albeck M et al. The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. Int J Cancer 1996 65 : 97 103.
10. Shohat M, Hodak E, Sredni B et al. Cytokine profile of patients with mycosis fungoides and the immunomodulatory effect of AS101. Acta Derm Venereol (Stockh) 2001 81 : 255 7.
11. Nicoletti I, Migliorati G, Pagliacci MC et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991 139 : 271 9.
12. Smiley ST, Reers M, Mottola-Hartshorn C et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 1991 88 : 3671 5.
13. Gazdar AF, Carney DN, Bunn PA et al. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 1980 55 : 409 17.
14. Kaltoft K, Bisballe S, Dyrberg T et al. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol 1992 28A : 161 7.
15. Cryns V, Yuan J. Proteases to die for. Genes Dev 1998 12 : 1551 70.
16. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997 326 : 1 16.
17. Hampton MB, Orrenius S. Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett 1997 414 : 552 6.
18. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 2000 29 : 323 33.
19. Nakazato T, Ito K, Ikeda Y et al. Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res 2005 11 : 6040 9.
20. Ghose A, Fleming J, Harrison PR. Selenium and signal transduction: roads to cell death and anti-tumour activity. Biofactors 2001 14 : 127 33.
21. Painter EP. The chemistry and toxicity of selenium compounds, with special reference to the selenium problem. Chem Rev 1941 28 : 179 213.
22. Seko Y, Imura N. Active oxygen generation as a possible mechanism of selenium toxicity. Biomed Environ Sci 1997 10 : 333 9.
23. Yan L, Spallholz JE. Generation of reactive oxygen species from the reaction of selenium compounds with thiols and mammary tumor cells. Biochem Pharmacol 1993 45 : 429 37.
24. Spallholz JE. On the nature of selenium toxicity and carcinostatic activity. Free Radic Biol Med 1994 17 : 45 64.
25. Sredni B, Gal R, Cohen IJ et al. Hair growth induction by the tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression. FASEB J 2004 18 : 400 2.
26. Albeck A, Weitman H, Sredni B, Albeck M. Tellurium compounds: selective inhibition of cysteine proteases and model reaction with thiols. Inorg Chem 1998 37 : 1704 12.
27. Sredni B, Geffen-Aricha R, Duan W et al. Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models. FASEB J 2007 21 : 1870 83.
28. Okun E, Dikshtein Y, Carmely A et al. The organotellurium compound ammonium trichloro(dioxoethylene-O,O') tellurate reacts with homocysteine to form homocystine and decreases homocysteine levels in hyperhomocysteinemic mice. FEBS J 2007 274 : 3159 70.
29. Frei GM, Lebenthal I, Albeck M et al. Neutral and positively charged thiols synergize the effect of the immunomodulator AS101 as a growth inhibitor of Jurkat cells, by increasing its uptake. Biochem Pharmacol 2007 74 : 712 22.
30. Izban KF, Ergin M, Qin JZ et al. Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol 2000 31 : 1482 90.
31. Giri DK, Aggarwal BB. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 1998 273 : 14008 14.
32. Sors A, Jean-Louis F, Pellet C et al. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 2006 107 : 2354 63.
33. Clopton DA, Saltman P. Low-level oxidative stress causes cell-cycle specific arrest in cultured cells. Biochem Biophys Res Commun 1995 210 : 189 96.
34. Chen Q, Ames BN. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci USA 1994 91 : 4130 4.
35. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004 350 : 1978 88.
36. Kim EJ, Hess S, Richardson SK et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005 115 : 798 812.
37. Vowels BR, Cassin M, Vonderheid EC et al. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992 99 : 90 4.
38. Vowels BR, Lessin SR, Cassin M et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994 103 : 669 73.
39. Asadullah K, Docke WD, Haeussler A et al. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996 107 : 833 7.
40. Hoppe RT, Medeiros LJ, Warnke RA et al. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995 32 : 448 53.
41. Strassmann G, Kambayashi T, Jacob CO et al. The immunomodulator AS-101 inhibits IL-10 release and augments TNF alpha and IL-1 alpha release by mouse and human mononuclear phagocytes. Cell Immunol 1997 176 : 180 5.
42. Kalechman Y, Zuloff A, Albeck M et al. Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator ammonium trichloro (dioxyethylene-O-O') tellurate. Blood 1995 85 : 1555 61.
43. Kalechman Y, Sredni B, Weinstein T et al. Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101. J Am Soc Nephrol 2003 14 : 620 30.